Clinical Trials Logo

Acute Lymphoid Leukemia clinical trials

View clinical trials related to Acute Lymphoid Leukemia.

Filter by:

NCT ID: NCT05959720 Recruiting - Clinical trials for Chemotherapeutic Toxicity

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

BRALLA
Start date: September 5, 2023
Phase:
Study type: Observational [Patient Registry]

In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic/follow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.

NCT ID: NCT05943093 Not yet recruiting - Clinical trials for Acute Lymphoid Leukemia

H19 in Acute Lymphoblastic Leukemia.

Start date: July 2023
Phase:
Study type: Observational

- Study the expression level of H19 gene in the samples from ALL patients by real-time PCR. - Correlate the expression level of H19 gene with the clinical presentation and laboratory data of those patients.

NCT ID: NCT05827549 Not yet recruiting - Clinical trials for Acute Lymphoid Leukemia

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

ReCALL
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This study is open-label, multi-center, prospective study, which targets childhood patients with recurred acute lymphostatic leukemia including recurrence around marrow. This study is designed to administer Idarubicin for Reinduction stage. Patients with recurrence are sorted into groups with their potential risk, and depending on their recurrence point, time, reaction to treatment etc, they are sorted into low-risk group, high-risk group, and highest-risk group. Patients with high-risk group are going to be given blinatumomab at consolidation stage before hematopoietic stem cell transplantation. Patients with low-risk group who are not suitable for hematopoietic stem cell transplantation are going to be maintaining maintenance therapy for 2 years for chemotherapy.

NCT ID: NCT05792007 Recruiting - Clinical trials for Acute Lymphoid Leukemia

Study of the Medullary Microenvironment in Acute Childhood Leukemia

MILA
Start date: October 26, 2023
Phase: N/A
Study type: Interventional

Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.

NCT ID: NCT05535855 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Start date: January 24, 2024
Phase: Phase 1
Study type: Interventional

This open-label, single arm Phase I trial aims to determine the safety and tolerability of anti-CD19 chimeric antigen receptor-expressing (CAR) T cells (UCD19 CAR T) in adults B-ALL that are in first complete remission with minimal residual disease (MRD) positivity. This trial will enroll 10 patients for apheresis and treatment with lymphodepleting chemotherapy followed by UCD19 CAR T cell infusion. Patients will be assessed for dose limiting toxicities (DLTs) (within 42 days after CAR T infusion), duration of B cell aplasia, overall response rate (at 1-, 3-, 6- and 12-months), and overall survival and event free survival (at 12- and 24- months) post UCD19 CAR T infusion.

NCT ID: NCT05442515 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Start date: December 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses. Objective: To test chimeric antigen receptor (CAR) therapy. CARs are genetically modified cells created from each patient s own blood cells. his trial will use a new type of CAR T-cell that is targeting both CD19 and CD22 at the same time. CD19 and CD22 are proteins found on the surface of most types of ALL. Eligibility: People aged 3 to 35 with ALL or related B-cell lymphoma that has not been cured by standard therapy. Design: Participants will be screened. This will include: Physical exam Blood and urine tests Tests of their lung and heart function Imaging scans Bone marrow biopsy. A large needle will be inserted into the body to draw some tissues from the interior of a bone. Lumbar puncture. A needle will be inserted into the lower back to draw fluid from the area around the spinal cord. Participants will undergo apheresis. Their blood will circulate through a machine that separates blood into different parts. The portion containing T cells will be collected; the remaining cells and fluids will be returned to the body. The T cells will be changed in a laboratory to make them better at fighting cancer cells. Participants will receive chemotherapy starting 4 or 5 days before the CAR treatment. Participants will be admitted to the hospital. Their own modified T cells will be returned to their body. Participants will visit the clinic 2 times a week for 28 days after treatment. Follow-up will continue for 15 years....

NCT ID: NCT05322850 Recruiting - Clinical trials for Acute Myeloid Leukemia

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

Start date: August 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.

NCT ID: NCT05316701 Recruiting - Clinical trials for Acute Myeloid Leukemia

Precision-T: A Randomized Phase III Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Orca-T
Start date: June 21, 2022
Phase: Phase 3
Study type: Interventional

This study will compare the safety and efficacy between patients receiving an engineered donor graft ("Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells) or standard-of-care (SOC) control in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation (MA-alloHCT) for hematologic malignancies. This posting represents the Phase III component of Precision-T. The Precision-T Ph1b component is described under NCT04013685.

NCT ID: NCT05166135 Completed - Clinical trials for Acute Myeloid Leukemia

Latin American Real-world Study in Acute Leukemia

LOYAL
Start date: December 10, 2021
Phase:
Study type: Observational

The objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (R/R) B-cell ALL and de novo AML in 4 Latin American countries.

NCT ID: NCT05150561 Recruiting - Lymphoma Clinical Trials

Muscle Dysfunction in Patients With Haematological Diseases

Start date: November 8, 2021
Phase:
Study type: Observational

PURPOSE: To evaluate the prevalence and prognostic value of sarcopenia in patients diagnosed with hematological cancer diseases.